DMAC Earnings Prediction
The chart below shows how DMAC performed 10 days before and after its earnings report, based on data from the past quarters. Typically, DMAC sees a -0.23% change in stock price 10 days leading up to the earnings, and a +5.67% change 10 days following the report. On the earnings day itself, the stock moves by +0.18%. This data can give you a slight idea of what to expect for the next quarter's release.
DMAC Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
--
--
--
Gross Margin
--
--
--
Operating Margin
--
--
--
Net Margin
--
--
--
EPS
-0.15
-25.00%
15.38%
No Data Available
DMAC Earnings Analysis
DiaMedica Therapeutics Inc. Common Stock Corporation (DMAC.O) Earnings Conference Call
Positive
Clinical Trial Activation Milestone: We now have 13 of our top 15 sites either fully activated or with signed clinical trial agreements, which is a significant milestone in our operational progress.
Patient Enrollment Strategy: We anticipate that these sites, especially our top 5, will enroll a disproportionately large number of patients, enhancing our trial's effectiveness.
Regulatory Approval Secured: We are pleased to have quickly secured regulatory approval from the South African Health Products Regulatory Authority, allowing us to proceed with our clinical trials.
DM199 in Preeclampsia Study: We believe DM199 has the potential to be disease-modifying in preeclampsia and hope to demonstrate this in the Part 1a of the study, which will be announced in the first half of 2025.
Enrollment Rate Acceleration: We expect that the protocol updates will accelerate enrollment rates with the addition of a subgroup of stroke patients that have the potential to be high responders to DM199 therapy.
Negative
Operating Activities Cash Usage: Net cash used in operating activities for the 9 months ended September 30, 2024 was $15.6 million compared to $14.9 million in the same period of the prior year, indicating an increase in cash used.
Cash Flow Challenges: The increase in cash used in operating activities resulted primarily from the combination of our increased net loss and the advance of deposit funds to vendors supporting the REMEDy 2 clinical trial during the current year period.
R&D Expense Increase: R&D expenses increased to $12.6 million for the 9 months ended September 30, 2024, compared to $9.4 million for the 9 months ended September 30, 2023, reflecting higher costs associated with the ongoing REMEDy 2 clinical trial.
Stable Administrative Expenses: Our general and administrative expenses were $1.9 million for each of the 3 months ended September 30, 2024 and 2023, indicating no reduction despite the ongoing cost management efforts.
Cash and Investments Decline: The combined cash, cash equivalents and investments balance is $50.2 million, down from $52.9 million as of December 31, 2023, reflecting a decrease in financial resources available.
DMAC FAQs
How does DMAC typically perform around its earnings report dates?
Is DiaMedica Therapeutics Inc. (DMAC) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
DMAC Earning Call Sentiment
DiaMedica Therapeutics Inc. (DMAC) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
DMAC.O
4.52%Positive
The earnings call highlights progress in clinical trials, extended cash runway, and potential expansion of the patient market for DM199, which are positive indicators. Although there are increased R&D expenses, they align with strategic trial expansions. The Q&A reveals optimism about reducing patient numbers and expanding commercial opportunities, suggesting confidence. Financials show stable G&A expenses and a manageable cash burn. The absence of major concerns and the potential for increased market interest support a positive outlook. However, the lack of market cap data limits the precision of the impact prediction.
